Table 1.
Baseline characteristics of the three study cohorts, 1997-2012, n = 6266
| Variables |
Propensity score-matched CKD patients |
|||
| Treated (n = 482) | Untreated (n = 1928) | Uninfected (n = 3856) | P1 value | |
| Sex | 0.38 | |||
| Men | 253 (52.5) | 979 (50.8) | 2032 (52.7) | |
| Women | 229 (47.5) | 949 (49.2) | 1824 (47.3) | |
| Age in yr | 58.5 ± 10.5 | 58.5 ± 13.7 | 58.4 ± 14.1 | 0.96 |
| Interferon-based therapy duration in yr | 0.5 ± 0.8 | - | - | |
| Comorbidity | ||||
| Diabetes | 228 (47.3) | 878 (45.5) | 1727 (44.8) | 0.55 |
| Hypertension | 290 (60.2) | 1150 (59.6) | 2315 (60.0) | 0.95 |
| Coronary heart disease | 182 (37.8) | 746 (38.7) | 1519 (39.4) | 0.73 |
| Hyperlipidemia | 239 (49.6) | 961 (49.8) | 1938 (50.3) | 0.93 |
| Cirrhosis | 120 (24.9) | 446 (23.1) | 892 (23.1) | 0.68 |
| ACEI/ARB use | 14 (2.9) | 37 (1.9) | 66 (1.7) | 0.19 |
| Enrollee category | < 0.0001 | |||
| 1 | 152 (31.5) | 546 (28.3) | 1332 (34.5) | |
| 2 | 10 (2.1) | 30 (1.6) | 61 (1.6) | |
| 3 | 255 (52.9) | 968 (50.2) | 1622 (42.1) | |
| 4 | 65 (13.5) | 384 (19.9) | 841 (21.8) | |
| Number of medical visits | 38.6 ± 25.6 | 34.4 ± 26.7 | 30.0 ± 25.0 | < 0.0001 |
| Charlson comorbidity index score | 4.2 ± 2.7 | 3.5 ± 2.6 | 3.2 ± 2.7 | < 0.0001 |
Data are presented as n (%).
1
For comparison among three cohorts. Categorical variables given as number (percentage); continuous variable, as mean ± SD. CKD: Chronic kidney disease; ACEI/ARB: Angiotensin converting enzyme inhibitor/angiotensin receptor blocker.